Personalis, Inc. (PSNL)
| Market Cap | 1.70B +110.5% |
| Revenue (ttm) | 69.67M -13.3% |
| Net Income | -107.18M |
| EPS | -1.10 |
| Shares Out | 106.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,220,045 |
| Open | 15.76 |
| Previous Close | 15.94 |
| Day's Range | 15.76 - 16.00 |
| 52-Week Range | 4.96 - 18.89 |
| Beta | 2.32 |
| Analysts | Hold |
| Price Target | 15.17 (-4.92%) |
| Est. Earnings | Nov 3, 2026 |
About PSNL
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.... [Read more]
Financial Performance
In 2025, Personalis's revenue was $69.65 million, a decrease of -17.69% compared to the previous year's $84.61 million. Losses were -$81.27 million, -0.02% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PSNL stock is "Hold." The 12-month stock price target is $15.17, which is a decrease of -4.92% from the latest price.
News
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featur...
Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental re...
Personalis downgraded to Neutral from Buy at BTIG
BTIG downgraded Personalis (PSNL) to Neutral from Buy without a price target The firm is increasingly confident that Tempus (TEM) will complete its acquisition of Personalis in the coming months.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Tempus AI upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Tempus AI (TEM) to Overweight from Neutral with a price target of $76, up from $56. The the pending acquisition of Personalis (PSNL) gives Tempus ownership of…
Personalis downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded Personalis (PSNL) to Hold from Buy with a $16.25 price target after the company announced an agreement to be acquired by Tempus AI (TEM) for $16.25 per share…
Personalis reports Q2 EPS (30c), consensus (28c)
Reports Q2 revenue $22.4M, consensus $16.79M. “We delivered another exceptional quarter of growth, highlighted by a 199% year-over-year and 33% sequential increase in clinical volume, with more than 1...
Personalis says not providing guidance or conducting earnings call
As a result of the announcement on July 20, 2026 that Personalis (PSNL) and Tempus AI (TEM) have entered into an Agreement and Plan of Merger, Personalis will no longer…
Personalis Reports Second Quarter Results and Recent Highlights
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended J...
Personalis Earnings release: Q2 2026
Personalis released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Personalis Quarterly report: Q2 2026
Personalis has published its Q2 2026 quarterly earnings report on August 4, 2026.
Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)
BALA CYNWYD, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Personalis price target raised to $16.25 from $11 at BTIG
BTIG raised the firm’s price target on Personalis (PSNL) to $16.25 from $11 and keeps a Buy rating on the shares after Tempus AI (TEM) said it will acquire Personalis…
Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a “Market Misread”
Tempus AI ($TEM) stock fell about 8% on Monday after the health technology company said it will acquire biotechnology company Personalis ($PSNL) in an all-stock deal valued at $1.7 billion. The…
Morgan Stanley sees strategic logic in Personalis deal despite financial hurdles
Morgan Stanley notes that Tempus AI (TEM) announced a definitive agreement to acquire Personalis (PSNL) for $16.25 per share, with the deal expected to close in late 2026 or early…
AI Daily: Tempus AI to acquire Personalis at enterprise value of $1.5B
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly. PERSONALIS…
Midday Fly By: Domino’s reports mixed Q2, Tempus AI to acquire Personalis
The major averages were mixed near noon as stocks look to rebound from last week’s technology-led selloff. Attention is turning to a week of megacap earnings that could determine whether…
Personalis downgraded to Hold from Buy at Needham
Needham downgraded Personalis (PSNL) to Hold from Buy after the company announced an agreement to be acquired by Tempus AI (TEM) for $16.25 per share in stock. The transaction is…
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink
Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.
Personalis downgraded to Hold from Buy at Lake Street
Lake Street analyst Thomas Flaten downgraded Personalis (PSNL) to Hold from Buy with a price target of $16.25, up from $11, after Tempus AI (TEM) announced a definitive agreement to…
Tempus to acquire Personalis for $1.5 billion
Tempus AI said on Monday it would acquire Personalis for about $1.5 billion to bringing its cancer test to the AI-enabled precision medicine firm's oncology portfolio.